Ciphergen Presents Protein Biomarker Discoveries

July 2002
Drug Discovery & Development;Jul/Aug2002, Vol. 5 Issue 7, p25
Reports on the presentation of studies involving the SELDI ProteinChip technology of Ciphergen Biosystems Inc. at the American Society for Mass Spectrometry Conference in Orlando, Florida. Use of the technology in proteomics research; Discovery of multiple protein biomarkers and biomarker patterns; Problems evaluated by the study.


Related Articles

  • Ciphergen Biosystems Introduces ProteinChip Biomarker System.  // Drug Discovery & Development;Nov2002, Vol. 5 Issue 10, p19 

    Reports that Ciphergen Biosystems Inc. has announced the release of its ProteinChip AutoBiomarker System at the 52nd Annual Meeting of the American Society of Human Genetics held in Baltimore, Maryland, from October 15-19, 2002. Features of the system; Company clientele.

  • European patent to Ciphergen.  // Medical Device Daily;5/31/2007, Vol. 11 Issue 104, p8 

    The article reports on a biomarker patent issued by the European Patent Office to Ciphergen Biosystems Inc. in 2007. It is noted that the biomarkers are for aiding in bladder cancer diagnosis when used in conjunction with the standard of care. The patent describes using mass spectrometry to...

  • Amassing Mass Spectrometry Tools. Frederickson, Robert M. // Bio-IT World;Jul2005, Vol. 4 Issue 7, p26 

    Focuses on several products for mass spectrometry, a tool in the effort to identify protein biomarkers of human disease. Features of Deep Proteome Research Services from Ciphergen Biosystems; ClinProt sample prefractionation technology from Bruker Daltonics; Software packages for analysis of...

  • Ovarian and Cervical Cancers Update.  // PharmaWatch: Cancer;Nov2005, Vol. 4 Issue 11, p6 

    The article presents information about various studies related to ovarian and cervical cancers. A phase II study of Avastin in advanced ovarian cancer has been suspended by Genentech Inc. after an increased rate of gastrointestinal bleeding was found in the patients. Cervical cancer vaccine...

  • Biomarker Detection Using Protein Arrays. Koppal, Tanuja // Drug Discovery & Development;Dec2002, Vol. 5 Issue 11, p35 

    Discusses the growing use of protein microarrays in detecting and identifying protein biomarkers for toxicology and early diagnosis of diseases. Detection of novel protein biomarkers through mass spectrometry; Identification of novel biomarkers through toxicological profiles of biochemical...

  • Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery. Wachter, Astrid; Bernhardt, Stephan; Beissbarth, Tim; Korf, Ulrike // Microarrays (2076-3905);2015, Vol. 4 Issue 4, p520 

    Mastering the systematic analysis of tumor tissues on a large scale has long been a technical challenge for proteomics. In 2001, reverse phase protein arrays (RPPA) were added to the repertoire of existing immunoassays, which, for the first time, allowed a profiling of minute amounts of tumor...

  • Systems biology approaches to disease marker discovery. Sharon, Donald; Rui Chen; Snyder, Michael // Disease Markers;2010, Vol. 28 Issue 4, p209 

    Our understanding of human disease and potential therapeutics is improving rapidly. In order to take advantage of these developments it is important to be able to identify disease markers. Many new high-throughput genomics and proteomics technologies are being implemented to identify candidate...

  • A Lateral Flow Protein Microarray for Rapid and Sensitive Antibody Assays. Gantelius, Jesper; Bass, Tarek; Sj√∂berg, Ronald; Nilsson, Peter; Andersson-Svahn, Helene // International Journal of Molecular Sciences;Nov2011, Vol. 12 Issue 11, p7748 

    Protein microarrays are useful tools for highly multiplexed determination of presence or levels of clinically relevant biomarkers in human tissues and biofluids. However, such tools have thus far been restricted to laboratory environments. Here, we present a novel 384-plexed easy to use lateral...

  • Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. Zlobec, Inti; Koelzer, Viktor H.; Dawson, Heather; Perren, Aurel; Lugli, Alessandro // Journal of Translational Medicine;2013, Vol. 11 Issue 1, p1 

    Background: Tissue microarray (TMA) technology revolutionized the investigation of potential biomarkers from paraffin-embedded tissues. However, conventional TMA construction is laborious, time-consuming and imprecise. Next-generation tissue microarrays (ngTMA) combine histological expertise...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics